osimertinib
astrazeneca
['adaura', 'lcsm,(-blcsm)', 'osimertinib', 'aura ,(-laura)']
key updates to adaura as presented at #esmo22 waning treatment effect observed for stage 2/3a disease upon osimertinib discontinuation at 3 years are we recurrence or delaying is 3 yrs enough adjuvant chemo remains important for these pts os benefit
#lcsm 
Thoracic/Head & Neck Medical Oncologist, Asst Professor @MDAndersonNews; Alum of @dukeu @muschealth @vumchealth @mdandersonnews; ??#cancer #lcsm; Views my own.